Author:
Langsjoen-P-H. Folkers-K. Lyson-K. Muratsu-K.
Lyson- T. Langsjoen-P.
Source:
Klin-Wochenschr. 1988 Jul 1. 66(13). P 583-90.
Journal Title:
KLINISCHE WOCHENSCHRIFT.
Abstract:
Coenzyme Q10 (CoQ10) is indispensable in mitochondrial
bioenergetics and for human life to exist. 88/115 patients
completed a trial of therapy with CoQ10 for cardiomyopathy.
Patients were selected on the basis of clinical criteria, X-
rays, electrocardiograms, echocardiography, and coronary
angiography. Responses were monitored by ejection fractions,
cardiac output, and improvements in functional classifications
(NYHA). Of the 88 patients 75%-85% showed statistically
significant increases in two monitored cardiac parameters.
Patients with the lowest ejection fractions (approx. 10%-30%)
showed the highest increases (115 delta %-210 delta %) and
those with higher ejection fractions (50%-80%) showed
increases of approx. 10 delta %-25 delta % on therapy. By
functional classification, 17/21 in class IV, 52/62 in class
III, and 4/5 in class II improved to lower classes. Clinical
responses appeared over variable times, and are presumably
based on mechanisms of DNA-RNA-protein synthesis of apoenzymes
which restore levels of CoQ10 enzymes in a deficiency state.
10/21 (48%) of patients in class IV, 26/62 (42%) in class III,
and 2/5 (40%) in class II had exceptionally low control blood
levels of CoQ10. Clinical responses on therapy with CoQ10
appear maximal with blood levels of approx. 2.5 micrograms
CoQ10/ml and higher during therapy
